Pomerantz Law Firm Issues Investor Alert on Class Action Against Pacira Biosciences, Inc.

Investor Alert: Pomerantz Law Firm's Class Action Against Pacira Biosciences, Inc.

In an important announcement for investors, Pomerantz LLP has officially filed a class action lawsuit against Pacira Biosciences, Inc. (NASDAQ: PCRX). This legal action is pertinent for those who have incurred losses on their investments in the company and pertains to allegations of securities fraud involving Pacira and some of its key officers and/or directors.

Key Details of the Lawsuit

Investors are advised to reach out to Pomerantz attorney Danielle Peyton via email at [email protected] or by calling 646-581-9980, toll-free at 888-4-POMLAW. Those interested in joining this class action are encouraged to include their mailing address, phone number, and the number of Pacira shares they purchased when contacting the firm. The deadline for investors to apply for Lead Plaintiff status is March 14, 2025.

The lawsuit arises from events tied to Pacira's claims against eVenus Pharmaceutical Laboratories, Inc., conducted in the U.S. District Court for the District of New Jersey. On August 9, 2024, Pacira faced a significant legal setback when the court invalidated its '495 patent, which pertained to the company's non-opioid pain treatment, Exparel. This legal ruling was based on findings of obviousness and anticipation.

This critical announcement resulted in a staggering decline in Pacira's stock price, plummeting by $10.66 per share or 47.67%, which left the closing share price at $11.70 on that day.

About Pomerantz LLP

Pomerantz LLP is recognized as one of the foremost law firms specializing in corporate securities and antitrust class action litigation. The firm, entrenched in a legacy established by its founder Abraham L. Pomerantz—a pioneer in the realm of securities class actions—has spent over 85 years fiercely advocating for the rights of victims of corporate misconduct and fraud. They boast a strong record of securing significant damage awards for affected class members.

As a dedicated legal entity, Pomerantz LLP continues to uphold the values and traditions set by its early founders, ensuring that the interests of investors are robustly represented in the courtroom.

For more details about the ongoing litigation and to access a copy of the complaint, investors can visit the firm’s website at www.pomerantzlaw.com.

Potential plaintiffs or investors wishing to remain informed about this class action are urged to act promptly, given the approaching deadlines and the significance of these developments within the financial markets.

Contact Information

For further inquiries, interested parties can contact Danielle Peyton at Pomerantz LLP through the details provided earlier or visit the firm's website.

Investors who believe they may have a claim due to losses suffered from investing in Pacira Biosciences are highly encouraged to explore their legal rights and potential recourse through this class action suit.

Attorney advertising. Past results do not guarantee future outcomes.